AbbVie

Open: 161.75 Close: 162.04 Change: 0.29

Our AI found some flaws in AbbVie Company Inc Stock.

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, dividend, ABBV, develop, drug, month, and the most common words in the summary are: abbvie, stock, best, market, job, dividend, news, . One of the sentences in the summary was: In 2022, Abbvies revenue was $58.05 billion.. Other searches related to this term that …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. stock falls t Tuesday, underperforms market - marketwatch.com. In 2022, Abbvies revenue was $58.05 billion.

Today's News

abbvie inc. stock falls t Tuesday, underperforms market - marketwatch.com. AbbVie Inc. stock fell t Tuesday. ImmunoGen Sued over alleged omissions in AbbVie Buyout Proxy. Immunogen Sued Over Alleged Omissions in ABbVIE Buyout proxy. In 2022, AbbVies revenue was $58.05 billion, an increase of 3.30% compared to the previous years $56.20 billion. Price Target $169.0 (4.30%) Analyst Consensus: Buy Stock Forecasts. AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the previous trading day. At 30.59 P/E GAAP (FWDWD), Abbvies stock is significantly more expensive. AbbVie is a specialty biopharmaceutical company which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. GlobalData tracks drug-specific phase transition and likelihood of approval scores. Sharx files defamation suit against AbbVie. The suit, which was assigned to Judge Mary Roberts, comes 11 months after Abbvie sent letters to patients and industry executives that discouraged them from doing business with Sharx. Abb vie recently announced the launch of its Parkinsons disease drug. AbbVie Inc.s (ABBV ) dividend yield is 3.84%, which means that for every $100 invested in the stock, investors would receive $3.84 in dividends per year. The companys ex-dividend date is January 12, 2024, meaning that buyers purchasing shares on or after that date will not be eligible for the next dividend. Sr. Manager – Global Pipeline Forecasting & Commercial Analytics, Oncology is to partner with the Director oncology Pipeline Forecast in the planning, execution, and delivery of forecasting and commercial analytics work in support of AbbVies Oncologia pipeline. The key responsibility of this role is to develop commercial forecasts. Produodopa is the first-to-market subcutaneous infusion of levodopa, and it holds potential to become the first choice pump for patients with advanced PD patients. AbbVie and Umoja Biopharma announce collaboration to develop CAR-T cell therapy candidates. P2P Business Partner Specialist - Eyecare Primary Mascot, Australia Req ID R00098476 Category Administrative Services Division AbbVie Apply Now. Engineer, Supplier Quality (Temporary 6 months) Engineer, supplier quality (temporary 6 month) Manage and lead efforts for the evaluation of change notifications from local and international suppliers. AbbVie shareholders who own ABBV stock before this date will receive Abbvies next dividend payment of $1.55 per share on Feb 15, 2024. The 17 top-selling drugs in 2020 produced more revenue in the United States than in the rest of the world combined.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, dividend, ABBV, develop, drug, month, and the most common words in the summary are: abbvie, stock, best, market, job, dividend, news, . One of the sentences in the summary was: In 2022, Abbvies revenue was $58.05 billion.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #best #market #job #dividend #news.